Skip to Content
Morningstar

GSK PLC ADR GSK

Morningstar Rating
Unlock
Stock XNYS Rating as of
$38.21 −0.17 (0.44%)
View Full Chart
As of Delayed Price Pre-Open: $38.08 −0.13
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

GSK, Pfizer, and Moderna: New RSV Vaccine Guidance Shrinks, but Long-Term Potential Remains

Damien Conover

The Centers for Disease Control and Prevention refined its RSV vaccine recommendations to adults aged 75 and older as well as those 60 to 74 years old at higher risk for RSV disease, which is a smaller group than the initial guidance for adults aged 60 and older. However, we don’t expect a major impact on the long-term potential for the RSV vaccines from GSK, Pfizer, and Moderna. We are maintaining our fair value estimates and moat ratings for the firms.

Read Full Report

Price vs Fair Value

View History
GSK is trading at a 832% premium.
Price
$38.21
Fair Value
$14.00
Uncertainty
Medium
1-Star Price
$82.80
5-Star Price
$39.20
Economic Moat
Vtqr
Capital Allocation
Kblhygqd

Bulls Say, Bears Say

Bulls

GSK's next-generation respiratory drugs and HIV drugs look poised for strong growth over the next three years.

Bears

HIV patent pressure to GSK's key drugs will likely begin in 2027, setting up a major hurdle for growth later in the decade.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GSK is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$38.38
Day Range
$37.81–38.32
52-Week Range
$33.68–45.93
Bid/Ask
$38.07 / $38.10
Market Cap
$77.91 Bil
Volume/Avg
4,454 / 3.8 Mil

Key Statistics

Price/Earnings (Normalized)
9.43
Price/Sales
2.04
Dividend Yield (Trailing)
3.88%
Dividend Yield (Forward)
3.94%
Total Yield
3.88%

Company Profile

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
70,200
Website
https://www.gsk.com

Competitors

Valuation

View More
Metric
GSK
MRK
PFE
Price/Earnings (Normalized)
 9.4358.8519.42
Price/Book Value
 4.468.011.71
Price/Sales
 2.045.292.85
Price/Cash Flow
 9.2218.6218.32
Price/Earnings
GSK
MRK
PFE

Financial Strength

Metric
GSK
MRK
PFE
Quick Ratio
 0.570.680.67
Current Ratio
 0.871.251.05
Interest Coverage
 8.943.97−0.26
Quick Ratio
GSK
MRK
PFE

Profitability

Metric
GSK
MRK
PFE
Return on Assets (Normalized)
 11.25%5.22%3.77%
Return on Equity (Normalized)
 51.21%13.56%8.51%
Return on Invested Capital (Normalized)
 22.40%8.29%5.75%
Return on Assets
GSK
MRK
PFE
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
VttmcjbszrGxrh$816.4 Bil
 Johnson & Johnson
JNJ
YmzknsrLzl$351.4 Bil
 Merck & Co Inc
MRK
DvftrdxrFhqh$323.5 Bil
 AbbVie Inc
ABBV
DwrxqtvjPsvc$293.1 Bil
 AstraZeneca PLC ADR
AZN
TyptbmfnpYlffj$236.9 Bil
 Roche Holding AG ADR
RHHBY
BvtskzztntZmg$222.4 Bil
 Novartis AG ADR
NVS
PsbvqvqTsk$217.9 Bil
 Amgen Inc
AMGN
QczpmcggzdWqg$166.7 Bil
 Pfizer Inc
PFE
KcpfppmLywk$157.7 Bil
 Sanofi SA ADR
SNY
NbypnlpgKnh$121.5 Bil

Sponsor Center